Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of RSV604 in Adults With RSV Infection Following Stem Cell Transplantation
NCT00232635Phase 2Completed
- Sponsor
- Arrow Therapeutics
- Start
- Sep 2005
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RSV-604 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Arrow Therapeutics. Primary endpoints: Reduction of viral load over time and 2-log reduction in RSV load at 3 days. Started Sep 2005; status: completed.
02
Drugs
RSV-604
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00232635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232635.